RESUMEN
Vaginal infections are extremely prevalent, particularly among women of reproductive age. Although they do not result in high mortality rates, these infections are associated with high levels of anxiety and reduction of quality of life. In most cases, topical treatment of vaginal infections has been shown to be at least as effective as oral treatment, resulting in higher local drug concentrations, with fewer drug interactions and adverse effects. Furthermore, the emergence of microbial resistance to chemotherapeutics and the difficulties in managing infection recurrences sustain the need for more effective local treatments. However, conventional dosage forms have been associated with low retention in the vagina and discomfort. Formulation strategies such as the development of bioadhesive, thermogelling systems and microtechnological or nanotechnological approaches have been proposed to improve delivery of traditional drugs, and other treatment modalities such as new drugs, plant extracts, and probiotics are being studied. This article reviews the recent strategies studied to improve the treatment and prevention of the commonest vaginal infections-namely, vaginal bacteriosis, aerobic vaginitis, vulvovaginal candidosis, and trichomoniasis-through the intravaginal route.
Asunto(s)
Antibacterianos/administración & dosificación , Sistemas de Liberación de Medicamentos/métodos , Tecnología Farmacéutica/métodos , Cremas, Espumas y Geles Vaginales/administración & dosificación , Vaginitis/tratamiento farmacológico , Administración Intravaginal , Antibacterianos/farmacocinética , Antibacterianos/uso terapéutico , Candidiasis Vulvovaginal/tratamiento farmacológico , Femenino , Humanos , Aceites Volátiles/uso terapéutico , Probióticos/uso terapéutico , Vaginitis por Trichomonas/tratamiento farmacológico , Vagina/fisiología , Absorción Vaginal , Cremas, Espumas y Geles Vaginales/farmacocinética , Cremas, Espumas y Geles Vaginales/uso terapéutico , Vaginosis Bacteriana/tratamiento farmacológicoRESUMEN
This review focuses on two formulation approaches, mucoadhesion and thermogelling, intended for prolonging residence time on vaginal mucosa of medical devices or drug delivery systems, thus improving their efficacy. The review, after a brief description of the vaginal environment and, in particular, of the vaginal secretions that strongly affect in vivo performance of vaginal formulations, deals with the above delivery systems. As for mucoadhesive systems, conventional formulations (gels, tablets, suppositories and emulsions) and novel drug delivery systems (micro-, nano-particles) intended for vaginal administration to achieve either local or systemic effect are reviewed. As for thermogelling systems, poly(ethylene oxide-propylene oxide-ethylene oxide) copolymer-based and chitosan-based formulations are discussed as thermogelling systems. The methods employed for functional characterization of both mucoadhesive and thermogelling drug delivery systems are also briefly described.
Asunto(s)
Sistemas de Liberación de Medicamentos/métodos , Cremas, Espumas y Geles Vaginales/administración & dosificación , Cremas, Espumas y Geles Vaginales/farmacocinética , Administración Intravaginal , Quitosano/química , Evaluación Preclínica de Medicamentos , Femenino , Humanos , Modelos Biológicos , Nanopartículas , Poloxámero/química , Supositorios/administración & dosificación , Supositorios/farmacocinética , Tecnología Farmacéutica , Vagina/fisiología , Absorción VaginalRESUMEN
The vagina stands as an important alternative to the oral route for those systemic drugs that are poorly absorbed orally or are rapidly metabolized by the liver. Drug permeation through the vaginal tissue can be estimated by using in vitro, ex vivo and in vivo models. The latter ones, although more realistic, assume ethical and biological limitations due to animal handling. Therefore, in vitro and ex vivo models have been developed to predict drug absorption through the vagina while allowing for simultaneous toxicity and pathogenesis studies. This review focuses on available methodologies to study vaginal drug permeation discussing their advantages and drawbacks. The technical complexity, costs and the ethical issues of an available model, along with its accuracy and reproducibility will determine if it is valid and applicable. Therefore every model shall be evaluated, validated and standardized in order to allow for extrapolations and results presumption, and so improving vaginal drug research and stressing its benefits.
Asunto(s)
Evaluación Preclínica de Medicamentos/métodos , Modelos Biológicos , Vagina/fisiología , Absorción Vaginal/fisiología , Animales , Línea Celular , Sistemas de Liberación de Medicamentos/métodos , Evaluación Preclínica de Medicamentos/normas , Femenino , Humanos , Reproducibilidad de los Resultados , Vagina/anatomía & histología , Vagina/citologíaRESUMEN
Sexually transmitted infections like HIV, HPV, and HSV-2, as well as unplanned pregnancy, take a huge toll on women worldwide. Woman-initiated multipurpose prevention technologies that contain antiviral/antibacterial drugs (microbicides) and a contraceptive to simultaneously target sexually transmitted infections and unplanned pregnancy are being developed to reduce these burdens. This review will consider products that are applied topically to the vagina. Rectally administered topical microbicides in development for receptive anal intercourse are outside the scope of this review. Microbicide and microbicide/contraceptive candidates must be rigorously evaluated in preclinical models of safety and efficacy to ensure that only candidates with favorable risk benefit ratios are advanced into human clinical trials. This review describes the comprehensive set of in vitro, ex vivo, and in vivo models used to evaluate the preclinical safety and antiviral efficacy of microbicide and microbicide/contraceptive candidates.